SkyCell is a purpose-led technology company innovating the pharmaceutical supply chain through a combination of proprietary software, hardware, and big data.
SkyCell designs and manufactures smart containers that allow pharmaceutical companies to predict, reduce, and control the risks associated with transporting temperature-sensitive drugs.
SkyCell was founded in 2013 by Richard Ettl and Nico Ros. The company is headquartered in Zurich, Switzerland.
SkyCell manufactures temperature-controlled door-to-door container solutions that allow pharma companies to optimise their supply chain by reducing, and even predicting, the risks associated with delivering sensitive drugs by air.
SkyCell's proprietary software solution combines simulation data with operational data (S+O data), enabling pharma companies to have real-time, end-to-end oversight of every shipment around the world, and its automated approval capability reduces quality approval time from an average of 14 days to just hours, getting drugs to consumers faster.
SkyCell transports more than US$1.5bn of pharma goods per month delivering hundreds of million doses of vaccines, cancer treatments, diabetes care and diagnostic solutions to patients around the world.
SkyCell is backed by Swiss Entrepreneurs Fund, Catalyst, MVM Partners LLP, UBS, DisruptAD, SHUAA, BCGE Bank, and others. The company raised $57M in a new round on Oct 31, 2023. This brings SkyCell's total funding to $190M to date. The latest round valued the company at a $600M post-money.